trending Market Intelligence /marketintelligence/en/news-insights/trending/nCqXgfaD7gC5kbFgUBi0gQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Agios' blood cancer combo therapy gains US FDA's breakthrough designation

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Agios' blood cancer combo therapy gains US FDA's breakthrough designation

Agios Pharmaceuticals Inc. has been granted the U.S. Food and Drug Administration's breakthrough therapy status for a combination therapy including its drug Tibsovo to treat patients with a certain type of blood cancer.

Tibsovo, or ivosidenib, in combination with Celgene Corp.'s Vidaza, or azacitidine, is aimed at treating newly diagnosed acute myeloid leukemia patients with a mutation called isocitrate dehydrogenase 1, or IDH1. The therapy was granted the breakthrough designation in the treatment of patients aged 75 years or older, who have additional conditions that prevent the use of chemotherapy.

Acute myeloid leukemia is a type of cancer in which too many immature white blood cells known as myeloblasts occur in the bone marrow and blood. This kind of cancer usually begins in the bone marrow and spreads into the blood. IDH1 is an enzyme that is encoded by the IDH1 gene on chromosomes.

The FDA's breakthrough therapy status expedites the development and review of drugs meant to treat serious or life-threatening conditions based on evidence indicating that the drug may show substantial improvement over available therapies.

Patients with newly diagnosed acute myeloid leukemia who cannot undergo chemotherapy are offered palliative care, according to Agios Chief Medical Officer Chris Bowden.

"Outcomes for newly diagnosed AML patients ineligible for intensive chemotherapy are still poor, and there are no approved options specifically for patients with an IDH1 mutation," Bowden said in the company's March 26 release.

In February, the FDA accepted Agios' application seeking expanded approval for Tibsovo in the treatment of patients with acute myeloid leukemia with IDH1 that has returned or is unresponsive to treatment.

Previously, Agios said Tibsovo showed treatment benefits in two of its studies — a phase 1/2 study and phase 1 study — for certain acute myeloid leukemia patients.

Tibsovo was approved by the agency in July 2018 as a treatment for acute myeloid leukemia with IDH1 that has returned or is unresponsive to treatment.